Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.

Authors:
Hyung soon Park
Hyung soon Park
Yale University
United States
Sejung Park
Sejung Park
Yonsei University College of Medicine
Hyo Jin Lee
Hyo Jin Lee
Chungnam National University Hospital
South Korea
Kyung A Kwon
Kyung A Kwon
Dongnam Institute of Radiological and Medical Sciences
Young Jin Choi
Young Jin Choi
Sejong General Hospital
Yu Jung Kim
Yu Jung Kim
Seoul National University College of Medicine
South Korea
Chung Mo Nam
Chung Mo Nam
Yonsei University College of Medicine
South Korea

Cancer Res Treat 2019 Apr 16. Epub 2019 Apr 16.

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Temsirolimus is effective in the treatment for metastatic non-clear cell renal cell carcinoma (nccRCC) with poor prognosis. We aim to investigate the efficacy and tolerability of temsirolimus in treatment of naïve Asian patients with metastatic/recurrent nccRCC.

Materials And Methods: From January 2008 to July 2017, data of treatment-naïve, metastatic/recurrent nccRCC patients, who were treated with temsirolimus according to the standard protocol, were collected. The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR), and tolerability of temsirolimus.

Results: Forty-four metastatic/recurrent nccRCC patients, 10 from prospective and 34 from retrospective groups, were enrolled; 24 patients (54%) were papillary type, and other histology subtypes included 11 (25%) chromophobe, 2 (5%) collecting duct, 1 (2%) Xp11.2 translocation, and 6 (14%) others. The median PFS and OS were 7.6 and 17.6 months, respectively. ORR was 11% and disease control rate was 83%. Patients with prior nephrectomy had longer PFS (HR 0.16; 95% confidence interval [CI], 0.06 to 0.42; p<0.001) and OS (HR, 0.15; 95% CI, 0.05 to 0.45; p<0.001). Compared to favorable/intermediate prognosis group, poor prognosis group had shorter median PFS (4.7 months vs. 7.6 months [HR, 2.91; 95% CI, 1.39 to 6.12, p=0.005] and median OS (9.2 months vs. 17.6 months [HR, 2.84; 95% CI, 1.23 to 6.56, p=0.015]).

Conclusion: Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.

Download full-text PDF

Source
http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2018.6
Publisher Site
http://dx.doi.org/10.4143/crt.2018.671DOI Listing
April 2019
4 Reads

Publication Analysis

Top Keywords

non-clear cell
8
metastatic/recurrent nccrcc
8
cell renal
8
nccrcc patients
8
patients
5
temsirolimusresults forty-four
4
forty-four metastatic/recurrent
4
tolerability temsirolimusresults
4
rate orr
4
orr tolerability
4
patients prospective
4
retrospective groups
4
patients 54%
4
54% papillary
4
enrolled patients
4
groups enrolled
4
papillary type
4
response rate
4
prospective retrospective
4
points survival
4

Similar Publications